1h Free Analyst Time
Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H1 2020Speak directly to the analyst to clarify any post sales queries you may have.
Summary
According to the recently published report 'Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H1 2020'; Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) pipeline Target constitutes close to 49 molecules. Out of which approximately 44 molecules are developed by companies and remaining by the universities/institutes.
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Macrophage colony-stimulating factor (M-CSF) is a secreted cytokine which influences hematopoietic stem cells to differentiate into macrophages or other related cell types. It plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. It promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. It plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. It required for normal male and female fertility. It promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration.
The report 'Macrophage Colony Stimulating Factor 1 Receptor - Pipeline Review, H1 2020' outlays comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 2, 2, 12, 5, 1, 12 and 8 respectively. Similarly, the universities portfolio in IND/CTA Filed, Preclinical and Discovery stages comprises 2, 2 and 1 molecules, respectively.
Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Musculoskeletal Disorders, Genetic Disorders, Gastrointestinal and Respiratory which include indications Solid Tumor, Colorectal Cancer, Gastric Cancer, Non-Small Cell Lung Cancer, Bile Duct Cancer (Cholangiocarcinoma), Epithelial Ovarian Cancer, Pancreatic Cancer, Tenosynovial Giant Cell Tumor, Fallopian Tube Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Peritoneal Cancer, Triple-Negative Breast Cancer (TNBC), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bladder Cancer, Breast Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Melanoma, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Recurrent Glioblastoma Multiforme (GBM), Soft Tissue Sarcoma, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Chronic Myelomonocytic Leukemia (CMML), Endometrial Cancer, Follicular Thyroid Cancer, Graft Versus Host Disease (GVHD), Kidney Cancer (Renal Cell Cancer), Liver Cancer, Medullary Thyroid Cancer, Metastatic Pancreatic Cancer, Neuroinflammation, Papillary Thyroid Cancer, Peripheral T-Cell Lymphomas (PTCL), Pigmented Villonodular Synovitis, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Salivary Gland Cancer, Thyroid Cancer, Acral Lentiginous Melanoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma, Adrenocortical Carcinoma (Adrenal Cortex Cancer), Advanced Malignancy, Anaplastic Large Cell Lymphoma (ALCL), Anaplastic Thyroid Cancer, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Angiosarcoma, Asthma, Auto Inflammatory Disease, Bone Metastasis, Brenner Tumor, Charcot-Marie-Tooth Disease Type I, Chondrosarcoma, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), Ependymoma, Esophageal Cancer, Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastroesophageal (GE) Junction Carcinomas, Gliosarcoma, High-Grade Glioma, Hormone Sensitive Breast Cancer, Inflammation, Lentigo Maligna Melanoma, Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis), Liposarcoma, Lung Adenocarcinoma, Malignant Mesothelioma, Malignant Neoplasms, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Biliary Tract Cancer, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Ovarian Cancer, Myelodysplastic Syndrome, Myelofibrosis, Natural Killer Cell Lymphomas, Neuroblastoma, Neuroendocrine Gastroenteropancreatic Tumors (GEP-NET), Neuroendocrine Tumors, Osteolysis, Osteoporosis, Osteosarcoma, Pain, Paraganglioma (Glomus Jugulare Tumor), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Pheochromocytoma, Primary Progressive Multiple Sclerosis (PPMS), ), Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Rhabdomyosarcoma, Sarcomas, Secondary Progressive Multiple Sclerosis (SPMS), Small-Cell Lung Cancer, Squamous Cell Carcinoma, Squamous Non-Small Cell Lung Cancer, Systemic Mastocytosis, Tauopathies, Thymic Carcinoma, Thymoma (Thymic Epithelial Tumor), Transformed Mycosis Fungoides, Uveal Melanoma and Von Hippel-Lindau Syndrome.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
- The report reviews Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Overview
- Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Therapeutics Development
- Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Therapeutics Assessment
- Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development
- Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Drug Profiles
- Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Dormant Products
- Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Discontinued Products
- Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Indications, H1 2020
- Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
- Number of Products under Development by Indications, H1 2020 (Contd..2), H1 2020
- Number of Products under Development by Indications, H1 2020 (Contd..3), H1 2020
- Number of Products under Development by Indications, H1 2020 (Contd..4), H1 2020
- Number of Products under Development by Indications, H1 2020 (Contd..5), H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Companies, H1 2020 (Contd..1)
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Products under Development by Companies, H1 2020 (Contd..2), H1 2020
- Products under Development by Companies, H1 2020 (Contd..3), H1 2020
- Products under Development by Companies, H1 2020 (Contd..4), H1 2020
- Products under Development by Companies, H1 2020 (Contd..5), H1 2020
- Products under Development by Companies, H1 2020 (Contd..6), H1 2020
- Products under Development by Companies, H1 2020 (Contd..7), H1 2020
- Products under Development by Companies, H1 2020 (Contd..8), H1 2020
- Products under Development by Companies, H1 2020 (Contd..9), H1 2020
- Products under Development by Companies, H1 2020 (Contd..10), H1 2020
- Products under Development by Companies, H1 2020 (Contd..11), H1 2020
- Number of Products under Investigation by Universities/Institutes, H1 2020
- Products under Investigation by Universities/Institutes, H1 2020
- Products under Investigation by Universities/Institutes, H1 2020 (Contd..1), H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Pipeline by AB Science SA, H1 2020
- Pipeline by Abbisko Therapeutics Co Ltd, H1 2020
- Pipeline by Amgen Inc, H1 2020
- Pipeline by Apollomics Inc, H1 2020
- Pipeline by BCI Pharma SA, H1 2020
- Pipeline by Bristol-Myers Squibb Co, H1 2020
- Pipeline by CrystalGenomics Inc, H1 2020
- Pipeline by CTI BioPharma Corp, H1 2020
- Pipeline by Deciphera Pharmaceuticals Inc, H1 2020
- Pipeline by Eli Lilly and Co, H1 2020
- Pipeline by Elixiron Immunotherapeutics Inc, H1 2020
- Pipeline by Elsalys Biotech SA, H1 2020
- Pipeline by F. Hoffmann-La Roche Ltd, H1 2020
- Pipeline by Flavocure Biotech LLC, H1 2020
- Pipeline by GigaGen Inc, H1 2020
- Pipeline by GlaxoSmithKline Plc, H1 2020
- Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020
- Pipeline by Hutchison MediPharma Ltd, H1 2020
- Pipeline by ImmunoForge Co Ltd, H1 2020
- Pipeline by Jiangsu Suzhong Pharmaceutical Group Co Ltd, H1 2020
- Pipeline by Merck & Co Inc, H1 2020
- Pipeline by NMS Group SpA, H1 2020
- Pipeline by Novartis AG, H1 2020
- Pipeline by Oncodesign SA, H1 2020
- Pipeline by Oncology Venture A/S, H1 2020
- Pipeline by Pfizer Inc, H1 2020
- Pipeline by Plexxikon Inc, H1 2020
- Pipeline by Provention Bio Inc, H1 2020
- Pipeline by Samjin Pharm Co Ltd, H1 2020
- Pipeline by Shattuck Labs Inc, H1 2020
- Pipeline by SignalChem Lifesciences Corp, H1 2020
- Pipeline by Suntec Medical (Taiwan) Inc, H1 2020
- Pipeline by Syndax Pharmaceuticals Inc, H1 2020
- Pipeline by The National Institute for Biotechnology in the Negev Ltd, H1 2020
- Pipeline by Transcenta Holding Ltd, H1 2020
- Pipeline by Turning Point Therapeutics Inc, H1 2020
- Dormant Products, H1 2020
- Dormant Products, H1 2020 (Contd..1), H1 2020
- Dormant Products, H1 2020 (Contd..2), H1 2020
- Dormant Products, H1 2020 (Contd..3), H1 2020
- Dormant Products, H1 2020 (Contd..4), H1 2020
- Dormant Products, H1 2020 (Contd..5), H1 2020
- Dormant Products, H1 2020 (Contd..6), H1 2020
- Dormant Products, H1 2020 (Contd..7), H1 2020
- Dormant Products, H1 2020 (Contd..8), H1 2020
- Discontinued Products, H1 2020
- Discontinued Products, H1 2020 (Contd..1), H1 2020
- Discontinued Products, H1 2020 (Contd..2), H1 2020
- Discontinued Products, H1 2020 (Contd..3), H1 2020
List of Figures
- Number of Products under Development by Stage of Development, H1 2020
- Number of Products under Development by Therapy Areas, H1 2020
- Number of Products under Development by Top 10 Indications, H1 2020
- Number of Products by Mechanism of Actions, H1 2020
- Number of Products by Stage and Mechanism of Actions, H1 2020
- Number of Products by Routes of Administration, H1 2020
- Number of Products by Stage and Routes of Administration, H1 2020
- Number of Products by Molecule Types, H1 2020
- Number of Products by Stage and Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AB Science SA
- Abbisko Therapeutics Co Ltd
- Amgen Inc
- Apollomics Inc
- BCI Pharma SA
- Bristol-Myers Squibb Co
- CrystalGenomics Inc
- CTI BioPharma Corp
- Deciphera Pharmaceuticals Inc
- Eli Lilly and Co
- Elixiron Immunotherapeutics Inc
- Elsalys Biotech SA
- F. Hoffmann-La Roche Ltd
- Flavocure Biotech LLC
- GigaGen Inc
- GlaxoSmithKline Plc
- Hanmi Pharmaceuticals Co Ltd
- Hutchison MediPharma Ltd
- ImmunoForge Co Ltd
- Jiangsu Suzhong Pharmaceutical Group Co Ltd
- Merck & Co Inc
- NMS Group SpA
- Novartis AG
- Oncodesign SA
- Oncology Venture A/S
- Pfizer Inc
- Plexxikon Inc
- Provention Bio Inc
- Samjin Pharm Co Ltd
- Shattuck Labs Inc
- SignalChem Lifesciences Corp
- Suntec Medical (Taiwan) Inc
- Syndax Pharmaceuticals Inc
- The National Institute for Biotechnology in the Negev Ltd
- Transcenta Holding Ltd
- Turning Point Therapeutics Inc
